The 100-Day Post-Acquisition Revenue Plan for Portfolio Companies

The deal closed. The board wants growth. And the single most common mistake happens in the first two weeks: changing the sales organization before anyone has actually diagnosed why it's underperforming. Real EBITDA movement in a portfolio company rarely comes from a dramatic reorg or a new go-to-market strategy slide. It comes from unglamorous, specific fixes — pricing discipline, pipeline conversion, rep-level productivity, clean data — found through diagnosis, not assumed from the diligence deck. A recent analysis of the operating partner model put it bluntly: EBITDA prefers plumbing over transformation theater.

Why the First 30 Days Determine the Outcome

McKinsey's private equity research has found that PE owners are consistently less confident in commercial capabilities — pricing, sales productivity, customer segmentation — than they are in cost reduction, even though the value creation math favors revenue-side fixes: a 1% pricing improvement raises profit by roughly 6% on average, compared to 3.8% and 1.1% for equivalent variable- and fixed-cost reductions. The commercial engine gets less rigor precisely where it has the most leverage. That gap shows up hardest in the first 100 days, when the pressure to show board-visible action is highest and the temptation to make structural changes before diagnosis is strongest.

Days 1-30: Diagnose

Before any team, process, or comp plan change: audit the pipeline, pull rep-level quota attainment data, and check CRM data quality. This isn't administrative — it's the only way to know whether an underperforming number is a people problem, a process problem, or a market problem, and those three require completely different fixes. Premature structural changes made before this diagnostic — replacing sales leadership, restructuring territories, changing comp before understanding what behavior it needs to drive — are the most common cause of missed first-year targets. What to pull in the first 30 days: trailing 12-month pipeline export by stage, rep-level quota attainment for the last 4 quarters, a CRM data quality spot-check (see the 6-Pillar Portfolio Company Sales Audit for the CRM/automation pillar), and a straight read on customer concentration and revenue quality (see the revenue quality framework).

Days 31-60: Scope

Once diagnosis is complete, separate findings into two buckets: quick wins (fixable in weeks, no structural change required — e.g., CRM hygiene, a broken follow-up cadence, an undocumented but obviously necessary sales process step) and structural fixes (require a comp plan change, a hire, a territory redesign, or a leadership change). Sequence quick wins first. They build credibility with the board and the team before the harder structural work starts, and they often fund part of the case for the structural changes that follow.

Days 61-100: Execute

This is where the first real structural changes land — but only the ones diagnosis actually justified, not the ones that seemed obvious on day one. Execute the highest-leverage structural fix first, not all of them simultaneously; portfolio companies rarely have the organizational bandwidth to absorb multiple major sales process changes at once without disrupting the pipeline that's already in motion.

The Board Update Cadence

Report on the Diagnose/Scope/Execute structure explicitly, not just on lagging revenue numbers. A board that sees "we diagnosed X, scoped Y, are executing Z" in month one has a materially different confidence level than a board that hears "the number is soft, we're working on it" — the same underlying situation, framed as a plan versus framed as a problem.

Common First-100-Day Mistakes

Replacing sales leadership before diagnosis. Sometimes the leader is the problem. Often the process they were never given the resources to fix is the problem. Diagnosis tells you which; assumption doesn't. Changing comp plans immediately. A comp plan redesign without a clear read on what behavior it needs to drive tends to solve last quarter's problem while creating a new one. Running diagnosis and execution in parallel. Under board pressure, it's tempting to start "fixing things" while diagnosis is still in progress. This is how quick wins get missed and structural fixes get built on incomplete information. Treating the 100-day plan as a one-time document instead of a cadence. The framework doesn't end at day 100 — it should repeat at a smaller scale every quarter for the rest of the hold period.

What This Looks Like When It's Done Right

The pattern across engagements that actually move the number: diagnosis happens before intervention, quick wins get sequenced ahead of structural change to build proof and credibility, and the plan is reported to the board as a structure, not a promise. Portfolio companies that skip straight to structural change on day one are betting the diligence deck's assumptions were already correct — which is precisely the assumption a real diagnostic exists to test. If you're inside the first 100 days of a hold and want the diagnostic done by someone who's run this end-to-end — not advised on it, run it — book a Portfolio Company Revenue Audit.